Diffusion Pharmaceuticals lead drug Trans Sodium Crocetinate (TSC) is an FDA Orphan-designated first-in-class small molecule that safely improves the results of cancer treatments such as radiation therapy and chemotherapy.

Diffusion Pharmaceuticals is a clinical stage biotechnology company focused on improving the results of cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, including multiple FDA Orphan-designated indications.


TSC modifies the tumor micro-environment, allowing enhanced therapeutic effects from radiation therapy and chemotherapy without the addition of harmful side effects.


Diffusion Pharmaceuticals is dedicated to extending the life expectancy of patients with treatment-resistant cancerous tumors, including GBM, pancreatic cancer and brain metastases.


Product Pipeline

Diffusion Pharmaceuticals is developing TSC for the improved treatment of life-threatening cancers in which tumor hypoxia (oxygen deprivation) diminishes the effectiveness of radiation therapy and chemotherapy.

Watch Diffusion Pharmaceuticals Inc. Overview Video

With CEO David Kalergis

Get the latests news first.

Subscribe to our newsletter.